The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to:

generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer

• perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors
• evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options
• evaluate biomarkers of drug sensitivity
• study primary and secondary (acquired) resistance in these models

Inclusion Criteria:

• In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent
• Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available
• Follow-up data should be available
• Patients with recurrent disease are allowed
• Written informed consent

All patients with a primary advanced or recurrent head and neck tumor.

• Inclusion preoperatively or before biopsy
• Written informed consent prior to surgery or biopsy